How I Treat Relapsed/Refractory Myeloma Including Novel Agents
Upon viewing this session, you will be able to describe current evidence-based therapies for treatment of relapsed/refractory multiple myeloma, summarize the efficacy and toxicity of available therapies, describe emerging novel immune and targeted single agent and combination therapies, and implement the optimal management of relapsed/refractory multiple myeloma using current and emerging therapies.
Kenneth C. Anderson, MD, Dana-Farber Cancer Institute
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members